Unknown

Dataset Information

0

Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial.


ABSTRACT:

SUBMITTER: Blay JY 

PROVIDER: S-EPMC8383051 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial.

Blay Jean-Yves JY   Serrano César C   Heinrich Michael C MC   Zalcberg John J   Bauer Sebastian S   Gelderblom Hans H   Schöffski Patrick P   Jones Robin L RL   Attia Steven S   D'Amato Gina G   Chi Ping P   Reichardt Peter P   Meade Julie J   Shi Kelvin K   Ruiz-Soto Rodrigo R   George Suzanne S   von Mehren Margaret M  

The Lancet. Oncology 20200605 7


<h4>Background</h4>Resistance to approved inhibitors of KIT proto-oncogene, receptor tyrosine kinase (KIT), and platelet-derived growth factor receptor α (PDGFRA) is a clinical challenge for patients with advanced gastrointestinal stromal tumours. We compared the efficacy and safety of ripretinib, a switch-control tyrosine kinase inhibitor active against a broad spectrum of KIT and PDGFRA mutations, with placebo in patients with previously treated, advanced gastrointestinal stromal tumours.<h4>M  ...[more]

Similar Datasets

| S-EPMC8571742 | biostudies-literature
| S-EPMC10238554 | biostudies-literature
| S-EPMC8053826 | biostudies-literature
| S-EPMC9401492 | biostudies-literature
| S-EPMC9746146 | biostudies-literature
| S-EPMC2915459 | biostudies-literature
| S-EPMC8995292 | biostudies-literature
| S-EPMC8685288 | biostudies-literature
| S-EPMC9362852 | biostudies-literature
| S-EPMC5531967 | biostudies-other